• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

Acetyloxy Diflorasone (CAS No. 3826-17-3): A Comprehensive Overview in Modern Pharmaceutical Research

Acetyloxy Diflorasone, a compound with the chemical identifier CAS No. 3826-17-3, represents a significant advancement in the field of pharmaceutical chemistry. This compound has garnered considerable attention due to its unique structural properties and its potential applications in therapeutic interventions. The introduction of acetyl groups into the diflorasone molecule enhances its pharmacological profile, making it a subject of extensive research in both academic and industrial settings.

The molecular structure of Acetyloxy Diflorasone is characterized by its ability to interact with specific biological targets, which has been a focal point in recent studies. Researchers have been particularly interested in its mechanism of action, which involves modulating inflammatory pathways and immune responses. This has opened up new avenues for treating conditions such as rheumatoid arthritis, psoriasis, and other autoimmune disorders where inflammation plays a critical role.

In recent years, the pharmaceutical industry has seen a surge in the development of novel corticosteroids that offer improved efficacy with reduced side effects. Acetyloxy Diflorasone stands out in this category due to its enhanced binding affinity to glucocorticoid receptors. This property not only increases its therapeutic potential but also suggests that it may be more effective at lower dosages compared to traditional corticosteroids.

One of the most compelling aspects of Acetyloxy Diflorasone is its potential as an anti-inflammatory agent. Studies have demonstrated that it can significantly reduce the production of pro-inflammatory cytokines such as TNF-α and IL-6. This effect is particularly noteworthy because it occurs without the typical side effects associated with long-term corticosteroid use, such as osteoporosis, hyperglycemia, and adrenal suppression.

The synthesis of Acetyloxy Diflorasone involves complex organic reactions that require precise control over reaction conditions. The introduction of the acetyl group at the appropriate position on the diflorasone backbone is crucial for achieving the desired pharmacological properties. Advances in synthetic methodologies have enabled researchers to produce this compound with high purity and yield, facilitating further research and development.

Preclinical studies have provided valuable insights into the pharmacokinetic profile of Acetyloxy Diflorasone. These studies indicate that the compound exhibits rapid absorption after oral administration and has a moderate half-life, allowing for once-daily dosing in clinical settings. Additionally, its metabolic stability suggests that it can be safely used over extended periods without significant accumulation or degradation.

The clinical potential of Acetyloxy Diflorasone has been explored in several Phase II trials targeting inflammatory and autoimmune diseases. Early results have shown promising outcomes, with patients experiencing significant reductions in disease activity and improved quality of life. These findings have generated excitement among clinicians and researchers who are looking for alternatives to existing treatments.

The development of Acetyloxy Diflorasone also highlights the importance of computational chemistry in modern drug discovery. Molecular modeling techniques have been instrumental in predicting how this compound interacts with biological targets at the atomic level. This approach has not only accelerated the design process but also provided insights into how structural modifications can enhance its therapeutic efficacy.

Regulatory considerations play a critical role in bringing Acetyloxy Diflorasone to market. Compliance with Good Manufacturing Practices (GMP) and rigorous safety testing are essential steps to ensure patient safety and efficacy. Collaborations between academic institutions and pharmaceutical companies have been crucial in navigating these regulatory pathways efficiently.

The future prospects for Acetyloxy Diflorasone are promising, with ongoing research focusing on expanding its therapeutic applications. Investigational studies are exploring its potential use in treating neuroinflammatory diseases, such as multiple sclerosis, where inflammation contributes significantly to disease progression. Additionally, research into combination therapies involving Acetyloxy Diflorasone with other bioactive compounds may further enhance its clinical utility.

In conclusion, Acetyloxy Diflorasone (CAS No. 3826-17-3) represents a significant advancement in pharmaceutical chemistry with substantial therapeutic potential. Its unique molecular structure, combined with its favorable pharmacological properties, positions it as a promising candidate for treating various inflammatory and autoimmune disorders. As research continues to uncover new applications and refine synthetic methodologies, Acetyloxy Diflorasone is poised to make a meaningful impact on patient care.

• 514-36-3(Fludrocortisone acetate)
• 2002-29-1(Flumethasone 21-pivalate)
• 23674-86-4(Difluprednate)
• 338-98-7(Isoflupredone acetate)
• 127-31-1(Fludrocortisone)
• 1177-87-3(Dexamethasone acetate)
• 2152-44-5(Betamethasone valerate)
• 2823-42-9(Flumethasone Acetate)
• 3801-06-7(Fluorometholone acetate)
• 987-24-6(betamethasone 21-acetate)